Opinion|Videos|July 4, 2024
Tailoring CDK4/6 Inhibitor Treatment to Patient Needs
A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores patient and disease-related factors that guide the decision to incorporate CDK4/6 inhibitors in this context.
Advertisement
Episodes in this series
- In the adjuvant treatment of HR+/HER2- early breast cancer, endocrine therapy has traditionally played a crucial role, with CDK4/6 inhibitors becoming more prominent in recent years through the monarchE and NATALEE trials. What factors related to the patient or disease influences the decision to utilize a CDK4/6 inhibitor in this setting?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Semaglutide More Than Doubled Likelihood of MASH Resolution
2
Once-Daily Pill Zasocitinib Clears Psoriasis at Toughest Sites
3
Wildfire Smoke Raises Asthma Risks as Fires Worsen Air Quality Across North America
4
Everyday Discrimination Linked to Health Care Access Barriers, Lower Preventive Care
5